Andrew Technologies, LLC announces the release of the first comparative fat graft survival study in which a liposuction device is demonstrated equivalent to standard syringe aspiration at 84 days post-grafting. Published in the November 2013 issue of Aesthetic Surgery Journal, this head to head study vs. traditional Coleman fat harvesting technique was led by Dr. Jeffrey Kenkel and Dr. Kathryn Davis of UT Southwestern in Dallas.
According to Mark S. Andrew, MD, Founder and Chief Scientific Officer of Andrew Technologies, "I congratulate Drs. Kenkel and Davis on their well designed and well-executed study, which showed HydraSolve lipoaspirate to be equivalent to the gold standard in fat grafting, the syringe aspiration method. The benefit of HydraSolve is that it can quickly deliver a large volume of high quality fat for autologous fat transfer, which the syringe method can not do."
HydraSolve achieves liquefaction of fat tissue by cell disaggregation, not by emulsification and the lysing of cell membranes. HydraSolve is the first liposuction device FDA cleared for autologous fat transfer
